FALLBACK Drug Patent Profile
✉ Email this page to a colleague
When do Fallback patents expire, and when can generic versions of Fallback launch?
Fallback is a drug marketed by Lupin and is included in one NDA.
The generic ingredient in FALLBACK is levonorgestrel. There are twenty drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the levonorgestrel profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fallback
A generic version of FALLBACK was approved as levonorgestrel by NOVEL LABS INC on February 22nd, 2013.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for FALLBACK?
- What are the global sales for FALLBACK?
- What is Average Wholesale Price for FALLBACK?
Summary for FALLBACK
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | FALLBACK at DailyMed |
US Patents and Regulatory Information for FALLBACK
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lupin | FALLBACK SOLO | levonorgestrel | TABLET;ORAL | 201446-001 | Jun 19, 2014 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
